Ключевые слова:
чрескожные коронарные вмешательства, гемостаз, липидный обмен, ЛПНП, фибриноген, D-димер, триглицериды, статины, тромбозБиблиографические ссылки
ESC/EACTS Guidelines on Cardiovascular Disease Prevention in Clinical Practice. European Society of Cardiology.Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies. Eur Heart J. 2021;42(34):3227–3337.DOI: 10.1093/eurheartj/eh ab484
Tan ST, Lim KH, Ng CH, Chan MYY, Lee CH. The Role of Lipid Profiles in Predicting Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. J Clin Med. 2025;14(1): 112.DOI: 10.3390/jcm1401 0112
Zhao W, Wu L, Li S, Wang X, Wang W. Effects of Lipid-Lowering Therapy on Hemostasis and Inflammation after Coronary Stenting: Insights into Mechanisms and Outcomes. Lipids Health Dis. 2025;24(1): 45.DOI: 10.1186/s12944-025-01987-6
Lopez-Candales A, Hernández-Suárez DF, Aponte-Rueda M, et al. Lipoprotein Subfractions and Platelet Reactivity in Patients with Coronary Artery Disease. JACC: Basic to Translational Science. 2024; 9(2):123–134.DOI: 10.1016/j.jacbts.2023.12.005
Reinhart M, Fernández A, Nabel EG. Inflammation, Lipids, and Thrombosis after PCI: Emerging Mechanistic Insights. Circulation. 2025;151(3):234–246.DOI: 10.1161/CIRCULATIONAHA.124.056789
Novel lipid profiles and atherosclerotic cardiovascular disease risk: a latent profile analysis. Lipids in Health and Disease. 2025.
Platelets, Biomarkers of Coagulation and Fibrinolysis, and Early Stent Thrombosis After Drug-Eluting Stent Implantation. Journal of Clinical Medicine. 2025.
Pharmacological targeting of coagulation factors XII and XI by function-blocking antibodies reduces stent-induced thrombosis. JACC: Basic to Tran-slational Science. 2024.
ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2021.
2025 ACC/AHA/ACEP/NAEMSP/SCAI Gui deline for the Management of Patients with Acute Coronary Syndromes. Circulation. 2025.